LPX Lipoxen

 

TIDMLPX 
 
RNS Number : 8938Z 
Lipoxen PLC 
30 September 2009 
 

+--------------------------------------+--------------------------------------+ 
| For immediate release                |                    30 September 2009 | 
|                                      |                                      | 
+--------------------------------------+--------------------------------------+ 
Lipoxen plc 
('Lipoxen' or 'the Company') 
Appointment of Director of Project Management 
 
 
Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the 
development of high-value differentiated biologicals, vaccines and siRNA 
delivery, is pleased to announce the appointment of Dr David Moss as Director of 
Project Management. Dr Moss's appointment builds on Lipoxen's announcement today 
that it has been appointed the lead member of the grant consortium for its 
controlled-release nanoparticle vaccine programme by the Technology Strategy 
Board, the Government organisation charged with driving UK innovation. 
 
 
Dr Moss joined the Company in early September and is charged not only with 
advancing the Technology Strategy Board programme in particular (given his 
substantial experience and track record in developing innovative vaccine 
formulations), but also with both strengthening the Lipoxen management team at 
the operating level and furthering the Company's Business Development efforts, 
especially but not exclusively, the initiation of new vaccine and siRNA 
projects. 
 
 
Dr Moss has almost thirty years of research, development and project management 
experience gained from roles in both academia and the private biotech sector. 
His focus during this period has been on the development of vaccines for 
veterinary and human applications. He joins Lipoxen from Cambridge Biostability 
Ltd (CBL) where he was Director of Research and was responsible for the 
company's entire research programme focused on the development of thermostable 
vaccines and biopharmaceuticals. This included the Technology Strategy 
Board-funded vaccine programme. Prior to CBL, he was Project Manager at Intervet 
UK (now Intervet Schering-Plough), a global veterinary vaccine and research and 
development company. 
 
 
Commenting on Dr Moss's appointment, M. Scott Maguire, CEO of Lipoxen, said: 
 
 
"Dr Moss brings to Lipoxen both substantial commercial experience as well as 
exceptional vaccine development knowledge including, very pertinently, a deep 
familiarity with the Technology Strategy Board programme. Lipoxen's influenza 
vaccine development project is a key element of the Company's preclinical 
pipeline and it will be driven forward by Dr Moss as part of his overall scope 
of responsibilities which also includes top level project management of the 
burgeoning schedule of initiatives being undertaken by the Company. We welcome 
David Moss to the Lipoxen management team and wish him every possible success in 
his new role." 
 
 
- Ends - 
For further information please contact: 
 
 
+-------------------------------------------------+-------------------------+ 
| Lipoxen plc                                     |    +44 (0)20 7389 5015  | 
+-------------------------------------------------+-------------------------+ 
| M. Scott Maguire, Chief Executive Officer       |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Singer Capital Markets (nominated adviser)      |     +44 (0)20 3205 7500 | 
+-------------------------------------------------+-------------------------+ 
| Jeff Keating / Claes Spång                      |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Noble & Company                                 |   +44 (0) 20 7763 2200  | 
+-------------------------------------------------+-------------------------+ 
| John Llewellyn-Lloyd / Sam Reynolds             |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Buchanan Communications                         |     +44 (0)20 7466 5000 | 
+-------------------------------------------------+-------------------------+ 
| Lisa Baderoon, Catherine Breen                  |                         | 
+-------------------------------------------------+-------------------------+ 
 
 
Notes for Editors 
 
 
About Lipoxen 
Lipoxen plc is a biopharmaceutical company focused on the development of new and 
improved biologic drugs and vaccines. Lipoxen has three proprietary patented 
technology platforms: 
 
 
1) PolyXen - for extending the efficacy and half life of biologic drugs 
2) ImuXen - for creating new vaccines and improving existing vaccines 
3) SiRNAblate - for the delivery of siRNA 
 
 
Lipoxen's technology is designed to improve the efficacy, safety, stability, 
biological half-life and immunologic characteristics of its products. 
 
 
Lipoxen has multiple drug and vaccine programmes in development. Two products 
are in clinical development, SuliXen, a long acting insulin and ErepoXen, a 
long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes 
vaccines against HIV, influenza and malaria and Factor VIII through an exclusive 
license with Baxter, the global healthcare company. 
 
 
The Company has a low-risk business model and out-licenses its proprietary 
technologies to biopharmaceutical companies that have strong manufacturing and 
marketing capabilities. Lipoxen currently has commercial agreements with some of 
the world's leading biotechnology and pharmaceutical companies including Baxter, 
Schering-Plough, Sanofi-Aventis, the Serum Institute of India Limited, 
Genentech, Amgen and Genzyme. Furthermore, Baxter led the GBP2.9 million 
fundraising that the Company announced in May 2009, with a US$1 million 
investment. 
 
 
Lipoxen, which was founded in 1997, now trades on the AIM Market of the London 
Stock Exchange under the ticker symbol LPX. More information can be found at the 
Company's website: www.lipoxen.com. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 BOALLMATMMITBPL 
 

Lipoxen (LSE:LPX)
과거 데이터 주식 차트
부터 3월(3) 2025 으로 3월(3) 2025

Lipoxen (LSE:LPX)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025